Our capabilities in agile software development and design combined with regulatory and market access expertise, ensures reduced time-to-market and frictionless deployment of safe, secure and effective companion apps that support patients beyond the pill.
Utilizing our established technology platform, we create tailored products designed to complement treatments and improve patient outcomes, across any indication.
Using qualitative interviews and other research methods to understand needs and pain points of patients and Health Care Professionals.
Our platform consists of a range of modules helping to address the challenges faced by patients on and off treatment — from adherence & side-effect management to mental health support.
We evaluate the digital solution with patients and HCPs, collect feedback, and further tailor the modules to be meet their needs.
The solution is available on the market. Depending on needs, the product can be unregulated or regulated. We advocate starting small and building from there!
Whether it's a digital patient support program or a regulated software-as-a-medical device (SaMD), digital companions can play a key role in facilitating the delivery of patient care and improving patient outcomes.
Eila® is a 12-week program for the treatment of tobacco dependence. The product is currently undergoing clinical trial in Germany to provide an evidence-based, clinically validated, and personalized digital therapy to patients.
In collaboration with:
This digital patient companion app provides treatment and support for patients with pulmonary fibrosis (PF), addressing low mood and anxiety. The product is currently undergoing clinical trial with results of the COMPANION study scheduled for release in January 2024.
In collaboration with:
